Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII

被引：10

作者：

Bajwa, N. ^{[1
]}

Enriquez, M. M. ^{[2
]}

Gorina, E.

Lemm, G.

机构：

[1] Bayer HealthCare, Specialty Med, Berkeley, CA 94701 USA

[2] Bayer HealthCare, Leverkusen, Germany

来源：

HAEMOPHILIA | 2009年 / 15卷 / 02期

关键词：

COHORT;

D O I：

10.1111/j.1365-2516.2008.01938.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：597 / 600

页数：4

共 5 条

[1]

Abshire TC, 2000, THROMB HAEMOSTASIS, V83, P811

[2] First-time development of FVIII inhibitor in haemophilia patients during the postoperative period [J].

Ghosh, K ;

Jijina, F ;

Shetty, S ;

Madkaikar, M ;

Mohanty, D .

HAEMOPHILIA, 2002, 8 (06) :776-780

[3] Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study [J].

Gouw, Samantha C. ;

van der Bom, Johanna G. ;

van den Berg, H. Marijke .

BLOOD, 2007, 109 (11) :4648-4654

[4] Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates [J].

Kempton, C. L. . ;

Soucie, J. . M. ;

Abshire, T. C. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (12) :2576-2581

[5] Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A - Results of an international clinical investigation [J].

Kreuz, W ;

Gill, JC ;

Rothschild, C ;

Manco-Johnson, MJ ;

Lusher, JM ;

Kellermann, E ;

Gorina, E ;

Larson, PJ .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (03) :457-467

← 1 →